N/A
N=9
Use of Continuous Glucose Monitors in Coronavirus Disease 2019 ICU and Potential Inpatient Settings
Covid19 · Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT05343624 ↗Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Feb 2023
Primary outcome: Primary: Time in Range — 21.6 percentage of time
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- continuous glucose monitoring (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University Hospitals Cleveland Medical Center
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time in Range |
21.6 | — |
| SECONDARY Number of Days CGM Worn |
5 | — |
| SECONDARY Hypoglycemia |
13.8; 0 | — |
Summary
The objective of the study is to improve glycemic control in inpatient/ICU settings using real- time continuous glucose monitors (CGM) data for insulin titration. It may help reduce Coronavirus disease 2019 patient contact with healthcare workers as well.
Eligibility Criteria
Inclusion Criteria
- Coronavirus disease 2019 tested positive patient
- Age over 18 years
- Admitted to Coronavirus disease 2019 specific ICU, with possible transfer to inpatient unit when stable
- Patients with known or acquired Type 1 or Type 2 Diabetes requiring insulin therapy during admission
Exclusion Criteria
- In state of active diabetic ketoacidosis (DKA) at time of enrollment
- Two or more vasopressors in use at time of sensor placement
- Unable to use at predetermined sensor site based on assessment of skin health
Data sourced from ClinicalTrials.gov (NCT05343624). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.